Atopic dermatitis is a multifactorial disease. Epidermal barrier impairment often plays the initial role in the initiation of the disease. Immune dysregulation of the innate and adaptive immunity plays a central role in the pathogenesis of atopic dermatitis. Alteration of the epidermal microbiome-host interaction serves a catalytic role in propagating this immune response. The understanding of this disease pathogenesis is important in generating treatment options, especially those such as biologic agents that can target a specific immune pathway.
Get full access to this article
View all access options for this article.
References
1.
SonessonA, PrzybyszewskaK, ErikssonS, et al.Identification of bacterial biofilm and the Staphylococcus aureus derived protease, staphopain, on the skin surface of patients with atopic dermatitis. Sci Rep, 2017; 7(1):8689.
2.
SilverbergJI, HanifinJM. Adult eczema prevalence and associations with asthma and other health and demographic factors: a US population-based study. J Allergy Clin Immunol, 2013; 132(5):1132–1138.
3.
EckertL, GuptaS, AmandC, et al.Impact of atopic dermatitis on health-related quality of life and productivity in adults in the United States: an analysis using the National Health and Wellness Survey. J Am Acad Dermatol, 2017; 77(2):274.e3–279.e3.
4.
BitscharK, WolzC, KrismerB, et al.Keratinocytes as sensors and central players in the immune defense against Staphylococcus aureus in the skin. J Dermatol Sci, 2017; 87(3):215–220.
5.
TsybikovNN, PetrishevaI, FefelovaEV, et al.Expression of TLR2 and TLR4 on peripheral blood monocytes during exacerbation of atopic dermatitis. Allergy Asthma Proc, 2015; 36(6):e140–e145.
6.
AokiW, UedaM. Characterization of antimicrobial peptides toward the development of novel antibiotics. Pharmaceuticals (Basel), 2013; 6(8):1055–1081.
7.
MarcinkiewiczM, MajewskiS. The role of antimicrobial peptides in chronic inflammatory skin diseases. Postepy Dermatol Alergol, 2016; 33(1):6–12.
8.
Di MeglioP, PereraGK, NestleFO. The multitasking organ: recent insights into skin immune function. Immunity, 2011; 35(6):857–869.
9.
NakatsujiT, ChenTH, NaralaS, et al.Antimicrobials from human skin commensal bacteria protect against Staphylococcus aureus and are deficient in atopic dermatitis. Sci Transl Med, 2017; 9(378).
HataTR, KotolP, BoguniewiczM, et al.History of eczema herpeticum is associated with the inability to induce human β-defensin (HBD)-2, HBD-3 and cathelicidin in the skin of patients with atopic dermatitis. Br J Dermatol, 2010; 163(3):659–661.
12.
JinS, ParkCO, ShinJU, et al.DAMP molecules S100A9 and S100A8 activated by IL-17A and house-dust mites are increased in atopic dermatitis. Exp Dermatol, 2014; 23(12):938–941.
13.
RiegS, SteffenH, SeeberS, et al.Deficiency of dermcidin-derived antimicrobial peptides in sweat of patients with atopic dermatitis correlates with an impaired innate defense of human skin in vivo. J Immunol, 2005; 174(12):8003–8010.
14.
MantiS, AmoriniM, CuppariC, et al.Filaggrin mutations and molluscum contagiosum skin infection in patients with atopic dermatitis. Ann Allergy Asthma Immunol, 2017; 119(5):446–451.
15.
KimBE, LeungDY, BoguniewiczM, et al.Loricrin and involucrin expression is down-regulated by TH2 cytokines through STAT-6. Clin Immunol, 2008; 126(3):332–337.
16.
DezmanK, KorosecP, RupnikH, et al.SPINK5 is associated with early-onset and CHI3L1 with late-onset atopic dermatitis. Int J Immunogenet, 2017; 44(5):212–218.
17.
DiWL, HennekamRC, CallardRE, et al.A heterozygous null mutation combined with the G1258A polymorphism of SPINK5 causes impaired LEKTI function and abnormal expression of skin barrier proteins. Br J Dermatol, 2009; 161(2):404–412.
18.
FeingoldKR.The outer frontier: the importance of lipid metabolism in the skin. J Lipid Res, 2009; 50(Suppl):S417–S422.
19.
DansoMO, BoitenW, van DrongelenV, et al.Altered expression of epidermal lipid bio-synthesis enzymes in atopic dermatitis skin is accompanied by changes in stratum corneum lipid composition. J Dermatol Sci, 2017; 88(1):57–66.
20.
SchommerNN, GalloRL. Structure and function of the human skin microbiome. Trends Microbiol, 2013; 21(12):660–668.
21.
WollinaU.Microbiome in atopic dermatitis. Clin Cosmet Investig Dermatol, 2017; 10:51–56.
22.
CavalcanteFS, AbadED, LyraYC, et al.High prevalence of methicillin resistance and PVL genes among Staphylococcus aureus isolates from the nares and skin lesions of pediatric patients with atopic dermatitis. Braz J Med Biol Res, 2015; 48(7):588–594.
23.
KennedyEA, ConnollyJ, HourihaneJO, et al.Skin microbiome before development of atopic dermatitis: early colonization with commensal staphylococci at 2 months is associated with a lower risk of atopic dermatitis at 1 year. J Allergy Clin Immunol, 2017; 139(1):166–172.
24.
IwamotoK, MoriwakiM, NiitsuY, et al.Staphylococcus aureus from atopic dermatitis skin alters cytokine production triggered by monocyte-derived Langerhans cell. J Dermatol Sci, 2017; 88(3):271–279.
25.
ByrdAL, DemingC, CassidySKB, et al.Staphylococcus aureus and Staphylococcus epidermidis strain diversity underlying pediatric atopic dermatitis. Sci Transl Med, 2017; 9(397).
26.
Laborel-PréneronE, BianchiP, BoraleviF, et al.Effects of the Staphylococcus aureus and Staphylococcus epidermidis secretomes isolated from the skin microbiota of atopic children on CD4+ T cell activation. PLoS One, 2015; 10(10):e0141067.
27.
TsilingiriK, FornasaG, RescignoM. Thymic stromal lymphopoietin: to cut a long story short. Cell Mol Gastroenterol Hepatol, 2017; 3(2):174–182.
28.
IndraAK.Epidermal TSLP: a trigger factor for pathogenesis of atopic dermatitis. Expert Rev Proteomics, 2013; 10(4):309–311.
29.
SoumelisV, RechePA, KanzlerH, et al.Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP. Nat Immunol, 2002; 3(7):673–680.
30.
YiL, ChengD, ZhangK, et al.Intelectin contributes to allergen-induced IL-25, IL-33, and TSLP expression and type 2 response in asthma and atopic dermatitis. Mucosal Immunol, 2017; 10(6):1491–1503.
31.
AubryC, MichonC, ChainF, et al.Protective effect of TSLP delivered at the gut mucosa level by recombinant lactic acid bacteria in DSS-induced colitis mouse model. Microb Cell Fact, 2015; 14:176.
32.
DongH, HuY, LiuL, et al.Distinct roles of short and long thymic stromal lymphopoietin isoforms in house dust mite-induced asthmatic airway epithelial barrier disruption. Sci Rep, 2016; 6:39559.
33.
FornasaG, TsilingiriK, CaprioliF, et al.Dichotomy of short and long thymic stromal lymphopoietin isoforms in inflammatory disorders of the bowel and skin. J Allergy Clin Immunol, 2015; 136(2):413–422.
34.
PalomaresO, AkdisM, Martin-FontechaM, et al.Mechanisms of immune regulation in allergic diseases: the role of regulatory T and B cells. Immunol Rev, 2017; 278(1):219–236.
CevikbasF, SteinhoffM. IL-33: a novel danger signal system in atopic dermatitis. J Invest Dermatol, 2012; 132(5):1326–1329.
37.
Guttman-YasskyE, KruegerJG, LebwohlMG. Systemic immune mechanisms in atopic dermatitis and psoriasis with implications for treatment. Exp Dermatol, 2017; 00:1–9.
38.
MatsunagaMC, YamauchiPS. IL-4 and IL-13 inhibition in atopic dermatitis. J Drugs Dermatol, 2016; 15(8):925–929.
39.
YaoX, ZhaW, SongW, et al.Coordinated regulation of IL-4 and IL-13 expression in human T cells: 3C analysis for DNA looping. Biochem Biophys Res Commun, 2012; 417(3):996–1001.
40.
ShangH, CaoXL, WanYJ, et al.IL-4 gene polymorphism may contribute to an increased risk of atopic dermatitis in children. Dis Markers, 2016; 2016:1021942.
41.
NaroznaB, HoffmannA, SobkowiakP, et al.Polymorphisms in the interleukin 4, interleukin 4 receptor and interleukin 13 genes and allergic phenotype: a case control study. Adv Med Sci, 2016; 61(1):40–45.
42.
ZhengT, OhMH, OhSY, et al.Transgenic expression of interleukin-13 in the skin induces a pruritic dermatitis and skin remodeling. J Invest Dermatol, 2009; 129(3):742–751.
43.
OhMH, OhSY, YuJ, et al.IL-13 induces skin fibrosis in atopic dermatitis by thymic stromal lymphopoietin. J Immunol, 2011; 186(12):7232–7242.
44.
IzuharaK, NunomuraS, NanriY, et al.Periostin in inflammation and allergy. Cell Mol Life Sci, 2017; 74(23):4293–4303.
45.
NamkungJH, LeeJE, KimE, et al.IL-5 and IL-5 receptor alpha polymorphisms are associated with atopic dermatitis in Koreans. Allergy, 2007; 62(8):934–942.
46.
FurueM, YamamuraK, Kido-NakaharaM, et al.Emerging role of interleukin-31 and interleukin-31 receptor in pruritus in atopic dermatitis. Allergy, 2018; 73(1):29–36.
47.
OtsukaA, NomuraT, RerknimitrP, et al.The interplay between genetic and environmental factors in the pathogenesis of atopic dermatitis. Immunol Rev, 2017; 278(1):246–262.
48.
SaitoS, AokiA, AraiI, et al.Regulation of TH2 responses by different cell types expressing the interleukin-31 receptor. Allergy Asthma Clin Immunol, 2017; 13:23.
49.
GittlerJK, ShemerA, Suarez-FarinasM, et al.Progressive activation of T(H)2/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. J Allergy Clin Immunol, 2012; 130(6):1344–1354.
50.
EsakiH, BrunnerPM, Renert-YuvalY, et al.Early-onset pediatric atopic dermatitis is TH2 but also TH17 polarized in skin. J Allergy Clin Immunol, 2016; 138(6):1639–1651.
51.
KasraieS, WerfelT. Role of macrophages in the pathogenesis of atopic dermatitis. Mediators Inflamm, 2013; 2013:942375.
52.
YawalkarN, KarlenS, EgliF, et al.Down-regulation of IL-12 by topical corticosteroids in chronic atopic dermatitis. J Allergy Clin Immunol, 2000; 106(5):941–947.
53.
HanH, RoanF, ZieglerSF. The atopic march: current insights into skin barrier dysfunction and epithelial cell-derived cytokines. Immunol Rev, 2017; 278(1):116–130.
54.
HoareC, Li Wan PoA, WilliamsH. Systematic review of treatments for atopic eczema. Health Technol Assess, 2000; 4(37):1–191.
55.
LimNR, LohmanME, LioPA. The role of elimination diets in atopic dermatitis—a comprehensive review. Pediatr Dermatol, 2017; 34(5):516–527.
56.
CampanaR, MoritzK, NeubauerA, et al.Epicutaneous allergen application preferentially boosts specific T cell responses in sensitized patients. Sci Rep, 2017; 7(1):11657.
57.
AltrichterS, KriehuberE, MoserJ, et al.Serum IgE autoantibodies target keratinocytes in patients with atopic dermatitis. J Invest Dermatol, 2008; 128(9):2232–2239.
58.
ChopraR, VakhariaPP, SacotteR, et al.Efficacy of bleach baths in reducing severity of atopic dermatitis: a systematic review and meta-analysis. Ann Allergy Asthma Immunol, 2017; 119(5):435–440.
59.
ZaneLT, ChandaS, JarnaginK, et al.Crisaborole and its potential role in treating atopic dermatitis: overview of early clinical studies. Immunotherapy, 2016; 8(8):853–866.
60.
SimpsonEL, BieberT, Guttman-YasskyE, et al.Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med, 2016; 375(24):2335–2348.
61.
RuzickaT, MiharaR. Anti–interleukin-31 receptor A antibody for atopic dermatitis. N Engl J Med, 2017; 376(21):2093.
62.
CorrenJ, ParnesJR, WangL, et al.Tezepelumab in adults with uncontrolled asthma. N Engl J Med, 2017; 377(10):936–946.
63.
HananiaNA, NoonanM, CorrenJ, et al.Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies. Thorax, 2015; 70(8):748–756.
